hCG and Clomid turn up side by side in fertility forums and in men's-health threads, often framed as alternatives. In the clinic they are mostly partners: one makes an egg grow, the other sets the moment it is released. In men they act at different points of the same hormone chain.
This page sets the two side by side from their US labels and the trials that test them together. The men's comparison is covered in depth on our enclomiphene vs hCG page, which holds the only randomised head-to-head trial; hCG in men more broadly is on hCG for men, and its labelled doses on our hCG dosage page. Peptide Lexicon's hCG entry explains the hormone. Nothing here is a recommendation; both are prescription medicines and every decision about them sits with the prescriber.
Side by side
| Clomid (clomiphene citrate) | hCG (chorionic gonadotropin) | |
|---|---|---|
| What it is | Small-molecule selective oestrogen receptor modulator, taken by mouth | Glycoprotein hormone, injected |
| Where it acts | Hypothalamus and pituitary: blocks oestrogen feedback so FSH and LH rise | Directly on the ovary or testis, acting like LH |
| US labelled uses | Ovulatory dysfunction in women desiring pregnancy | Urinary hCG: prepubertal cryptorchidism; selected hypogonadotropic hypogonadism in males; ovulation induction after menotropins. Recombinant (Ovidrel): final follicle maturation in IVF; ovulation induction |
| Labelled for men? | No — "no adequate or well-controlled studies" in male infertility | Yes, for hypogonadotropic hypogonadism |
| Course limit on the label | About six cycles in total | None stated |
| Leading warnings | Visual symptoms, ovarian hyperstimulation, multiple pregnancy | Ovarian hyperstimulation, cyst rupture, multiple births, arterial thromboembolism |
Clomid label (Cosette, January 2025) and generic clomiphene label (September 2025); urinary chorionic gonadotropin labels (March and April 2025) — read via openFDA, 28 October 2026.
How they are used together
The Clomid label sets out a cycle: a course starts on or about day 5, and "properly timed coitus in relationship to ovulation is important". In practice, many clinics monitor the follicle by ultrasound and give an hCG trigger shot when it is mature, to time intercourse or intrauterine insemination (IUI). The hCG labels themselves do not describe this: the urinary products' ovulation indication is for women "appropriately pretreated with human menotropins"; the recombinant product, Ovidrel (choriogonadotropin alfa, label December 2023), covers final follicle maturation in IVF after FSH and ovulation induction in anovulatory women; and none of the three labels names clomiphene. The Clomid label, for its part, says there is "no universally accepted standard regimen for combined therapy" with other ovulation-inducing drugs.
So the question the trials ask is not "hCG or Clomid" but "Clomid alone, or Clomid plus an hCG trigger?"
What the trigger trials found
Cochrane, 2014. George and colleagues' review of ovulation triggers in anovulatory women found two randomised trials (305 women), both comparing urinary hCG with no trigger in clomiphene cycles. Adding hCG:
| Outcome | Odds ratio (95% CI) | Evidence quality |
|---|---|---|
| Live birth | 0.97 (0.52 to 1.83) | Low |
| Ovulation | 0.99 (0.36 to 2.77) | Low |
| Clinical pregnancy | 1.02 (0.56 to 1.89) | Low |
| Miscarriage (54 pregnant women) | 1.19 (0.17 to 8.23) | Low |
The authors concluded the evidence was "inadequate to recommend or refute" hCG as a trigger in clomiphene cycles. Ovarian hyperstimulation and adverse events were not reported as outcomes in either trial. Two of the review's four authors had written one of the included trials, which the review declares.
Insemination timing, 2023. Potapragada and colleagues (Obstetrics & Gynecology, July 2023) pooled 13 studies — five retrospective cohorts, four cross-sectional, two randomised trials and two randomised crossovers — of IUI in natural cycles or cycles on clomiphene or letrozole. Pregnancy odds after timing by hCG trigger and by monitoring the body's own LH surge did not differ (OR 0.92, 95% CI 0.69 to 1.22). Most of the evidence was observational.
Neither review shows harm from the trigger; neither shows a benefit in the outcome that matters most. That is the honest state of a very common practice.
Side effects, as each label frames them
Clomid reports rates from its clinical studies (n = 8,029): ovarian enlargement 13.6%, hot flushes 10.4%, abdominal-pelvic discomfort or bloating 5.5%, nausea and vomiting 2.2%, breast discomfort 2.1%, visual symptoms 1.5%, headache 1.3%, abnormal uterine bleeding 1.3%. Its warnings single out visual symptoms — blurring, spots, flashes — which rise with dose and duration and "may be irreversible, especially with increased dosage or duration". Of the pregnancies reported in the trial programme (2,635, with outcome known for 2,369), 7.98% were multiple: 6.9% twins, 0.5% triplets, 0.3% quadruplets, 0.1% quintuplets.
hCG labels list headache, irritability, restlessness, depression, fatigue, oedema, precocious puberty, gynaecomastia and injection-site pain, without rates. For ovulation induction they name four serious risks: ovarian hyperstimulation, rupture of ovarian cysts, multiple births and arterial thromboembolism, plus anaphylaxis with urinary-derived products. The full hCG record is on our hCG side effects page.
Both labels carry a line the other does not need: Clomid's six-cycle limit, and the capital-letter statement on both hCG labels we read that hCG "has not been demonstrated to be effective adjunctive therapy in the treatment of obesity" — the background to our hCG diet page.
The men's question
In men, clomiphene raises the body's own LH and testosterone by acting on the pituitary; hCG stands in for LH at the testis. The Clomid label does not cover men: it states there are "no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility", and that "testicular tumors and gynecomastia have been reported in males using clomiphene", cause unknown. Clomiphene's use in men is off-label.
The one randomised trial comparing the two in men, a 2025 meta-analysis that rated it low certainty, and the refused application for enclomiphene — the purified isomer of clomiphene — are set out on our enclomiphene vs hCG page rather than repeated here. Related comparisons: gonadorelin vs hCG and hCG vs kisspeptin.
What is not established
- Whether an hCG trigger improves live births in clomiphene cycles — two small trials, low-quality evidence, no effect detected.
- A standard combined regimen — the Clomid label says none is accepted.
- Clomiphene's effect on male fertility outcomes under controlled conditions, per its own label.
- Anything about products sold online as research hCG, which carry no label and no quality record; our guide to reading a certificate of analysis explains what a seller's document can show.
Fertility treatment, in women or men, is planned with a fertility specialist; visual changes on clomiphene and abdominal pain or rapid weight gain after an hCG injection are reasons to contact one promptly.
Sources and dates
- Clomid (clomiphene citrate tablets) prescribing information, Cosette Pharmaceuticals, January 2025, and generic clomiphene citrate (Rising), September 2025, via openFDA — read 28 October 2026.
- Chorionic gonadotropin for injection prescribing information (Fresenius Kabi, April 2025; NuCare, March 2025) and Ovidrel (choriogonadotropin alfa) prescribing information, December 2023, via openFDA — read 28 October 2026.
- George K, Kamath MS, Nair R, Tharyan P. Ovulation triggers in anovulatory women undergoing ovulation induction. Cochrane Database Syst Rev 2014;(1):CD006900 — abstract read 28 October 2026.
- Potapragada NR et al. Intrauterine insemination after human chorionic gonadotropin trigger or luteinizing hormone surge: a meta-analysis. Obstet Gynecol 2023;142(1):61–70 — abstract read 28 October 2026.